Indian Equities
Latest news, explainers and analysis on Indian Equities. Tracking 12 stories on Arth Vani.
Connected in the graph
Latest on Indian Equities
Sakar Healthcare Stock Surges 350% in 5 Years on Strong Profit Growth
Sakar Healthcare's share price saw a significant jump, trading at ₹817.45 today, following a 120% year-on-year rise in net profit for Q1 FY27. The stock has delivered a remarkable 350% return over the past five years.
Market Optimism Grows: Finolex Cables, Zydus Wellness Among Analyst Picks
Indian stock markets recently closed higher, buoyed by positive global signals, falling crude oil prices, and optimism about a potential India-US trade agreement. Amid this positive sentiment, analysts are recommending Finolex Cables and Zydus Wellness, citing their strong technical indicators and potential for future growth.
Indian Equities Show Resilience as Foreign Selling Slows, Domestic Buying Continues
Foreign investors significantly reduced their selling of Indian shares in June, indicating improved market sentiment. This reduced foreign outflow, combined with ongoing strong buying by domestic investors, is providing crucial support and resilience to the Indian equity market.
Reliance Shares Rise After Q1 Results: What it Means for Your Portfolio
Reliance Industries saw its share price increase by 2.50% to ₹1,328.80 after its Q1 2026 results. This movement has sparked discussions among investors about the future prospects of the stock.
TCS and ICICI Bank Lead ₹1.54 Lakh Crore Surge in Top 10 Firms' Valuation
Five of India's top 10 most valued companies added a combined ₹1.54 lakh crore to their market capitalization last week. IT giant TCS emerged as the biggest gainer, while HDFC Bank and Bharti Airtel saw their valuations dip despite a positive week for the broader equity markets.
US Futures Tick Up as Strong Quarter Ends, Indian Market Eyes Global Cues
US stock futures showed modest upward movement as a strong financial quarter drew to a close. This development is being closely watched by Indian investors, as trends in global markets often set the tone for domestic sentiment and investment decisions.
Indian Markets Dip for Second Day Amid Caution; Nifty at Crucial 23,800 Level
Indian stock markets concluded their second consecutive session with declines, reflecting a cautious investor sentiment. Despite easing global tensions, Sensex fell by nearly 250 points and Nifty dropped over 80 points. Analysts are closely watching Nifty's crucial support level of 23,800 for any signs of a market recovery.
IFCI Shares Rebound 6% as Retail Investors Bet on NSE IPO Momentum
IFCI shares witnessed a strong recovery on Friday, jumping 6% after a sharp sell-off in the previous session. The stock's performance is closely tied to optimism surrounding the potential listing of the National Stock Exchange (NSE).
Eyes on FY27: Why Domestic Earnings Growth Matters More Than Global Headlines
While global tensions show signs of easing, Indian stock markets are shifting focus toward long-term corporate performance. Experts suggest that the next major rally in Indian equities will be driven by earnings projections for the 2027 fiscal year rather than international macro events.
Cheap Oil and Firm Rupee to Boost Indian Corporate Earnings, Says Deepak Shenoy
Lower global crude oil prices and a stronger Indian Rupee are expected to improve profit margins for Indian companies. Experts believe this creates a favorable landscape for retail investors, particularly in the metals and healthcare sectors.
Bullish Signals: 14 Stocks Cross Key 200-Day Average as Market Momentum Shifts
Technical indicators suggest a positive shift for 14 specific stocks that have recently climbed above their 200-day Daily Moving Average (DMA). This movement is often viewed by market analysts as a transition from a long-term decline to a potential sustained uptrend.
Concord Biotech Shares Jump 6% Following USFDA Approval for Arthritis Tablets
Shares of Concord Biotech rose sharply after the company received a green light from the US health regulator for its Tofacitinib tablets. This approval allows the firm to enter a lucrative $500 million US market for rheumatoid arthritis treatments.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.